These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1704437)

  • 1. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
    Simpson PJ; Schelm JA; Smith GF
    J Pharmacol Exp Ther; 1991 Feb; 256(2):780-6. PubMed ID: 1704437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of serotonin (5HT2) receptor blockade in myocardial reperfusion injury: effects of LY53857 in a canine model of myocardial infarction.
    Simpson PJ; Schelm JA; Jakubowski JA; Smallwood JK
    J Pharmacol Exp Ther; 1991 Sep; 258(3):979-85. PubMed ID: 1653847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood cardioplegia supplementation with the sodium-hydrogen ion exchange inhibitor cariporide to attenuate infarct size and coronary artery endothelial dysfunction after severe regional ischemia in a canine model.
    Muraki S; Morris CD; Budde JM; Zhao ZQ; Guyton RA; Vinten-Johansen J
    J Thorac Cardiovasc Surg; 2003 Jan; 125(1):155-64. PubMed ID: 12538999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1.
    Hartman JC; Anderson DC; Wiltse AL; Lane CL; Rosenbloom CL; Manning AM; Humphrey WR; Wall TM; Shebuski RJ
    Cardiovasc Res; 1995 Jul; 30(1):47-54. PubMed ID: 7553723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation.
    Simpson PJ; Mickelson J; Fantone JC; Gallagher KP; Lucchesi BR
    J Pharmacol Exp Ther; 1988 Feb; 244(2):619-24. PubMed ID: 2831348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of myocardial ischemia-reperfusion injury by KT-362, a new intracellular calcium antagonist in anesthetized dogs.
    Pelc LR; Farber NE; Warltier DC; Gross GJ
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):586-93. PubMed ID: 2470996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.
    Black SC; Gralinski MR; Friedrichs GS; Kilgore KS; Driscoll EM; Lucchesi BR
    Cardiovasc Res; 1995 May; 29(5):629-36. PubMed ID: 7606750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial and myocardial cell protection by a cysteine-containing nitric oxide donor after myocardial ischemia and reperfusion.
    Lefer DJ; Nakanishi K; Vinten-Johansen J
    J Cardiovasc Pharmacol; 1993; 22 Suppl 7():S34-43. PubMed ID: 7504767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline.
    Dauber IM; Lesnefsky EJ; Ashmore RC; Martel DM; Sheridan FM; Weil JV; Horwitz LD
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1250-6. PubMed ID: 1312165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
    Simpson PJ; Schelm JA; Smallwood JK; Clay MP; Lindstrom TD
    J Cardiovasc Pharmacol; 1992 Jun; 19(6):987-95. PubMed ID: 1376823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on prolonged acute regional ischemia. IV. Aggressive surgical treatment for intractable ventricular fibrillation after acute myocardial infarction.
    Beyersdorf F; Acar C; Buckberg GD; Partington MT; Okamoto F; Allen BS; Bugyi HI; Young HH
    J Thorac Cardiovasc Surg; 1989 Oct; 98(4):557-66. PubMed ID: 2796363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog.
    Gu Q; Yang XP; Bonde P; DiPaula A; Fox-Talbot K; Becker LC
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):320-8. PubMed ID: 17204912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term inhibition of myocardial infarction by postconditioning during reperfusion.
    Mykytenko J; Kerendi F; Reeves JG; Kin H; Zatta AJ; Jiang R; Guyton RA; Vinten-Johansen J; Zhao ZQ
    Basic Res Cardiol; 2007 Jan; 102(1):90-100. PubMed ID: 17003965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size.
    Hahn RA; MacDonald BR; Simpson PJ; Potts BD; Parli CJ
    J Pharmacol Exp Ther; 1990 Apr; 253(1):58-66. PubMed ID: 2158553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion.
    Zhao ZQ; Nakamura M; Wang NP; Velez DA; Hewan-Lowe KO; Guyton RA; Vinten-Johansen J
    J Surg Res; 2000 Dec; 94(2):133-44. PubMed ID: 11104653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amelioration of ischemia/reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146).
    Sasamori J; Aihara K; Yoneyama F; Sato I; Kogi K; Takeo S
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):614-20. PubMed ID: 16680077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis.
    Apprill PG; Ashton J; Guerrero J; Glas-Greenwalt P; Buja LM; Willerson JT
    Am Heart J; 1987 Apr; 113(4):898-906. PubMed ID: 3565240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function.
    Simpson PJ; Todd RF; Mickelson JK; Fantone JC; Gallagher KP; Lee KA; Tamura Y; Cronin M; Lucchesi BR
    Circulation; 1990 Jan; 81(1):226-37. PubMed ID: 2153476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion.
    Simpson PJ; Fantone JC; Mickelson JK; Gallagher KP; Lucchesi BR
    Circ Res; 1988 Dec; 63(6):1070-9. PubMed ID: 2461814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.